tiprankstipranks

iKena Oncology expects cash to meet operating requirements into 2H26

As of December 31, 2023, the Company had cash, cash equivalents, and marketable securities of $175.5 million, which the Company believes will be sufficient to fund operations into the second half of 2026.

Protect Your Portfolio Against Market Uncertainty

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on IKNA:

Disclaimer & DisclosureReport an Issue